Abstract: A compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.17, R.sup.18 and R.sup.1 are as defined below. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

Abstract: A parenteral formulation for 25-cyclohexyl-avermectin Bl, compound (I), which is effective against both internal and external parasites, is well tolerated by animals on both subcutaneous and intramuscular administration and is compatible with conventional injection equipment. ##STR1## The solution comprises compound (I), in a solvent consisting of from 50 to 95% by volume of sesame oil with the remainder ethyl oleate.

Abstract: A hydrochloride salt of an Apo B secretion/MTP inhibitor, methods of making the salt, methods of using the salt and pharmaceutical compositions containing the salt are disclosed.

Abstract: This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, Alzheimer's agents or anti-acne agents.

Abstract: A method of preventing non-cardiac tissue damage resulting from ischemia and/or hypoxia, comprising administering to a patient in need of such treatment an effective amount of an glycogen phosphorylase inhibitor.

Abstract: This invention relates to certain steroidal glycosides useful as hypocholesterolemic agents and antiatherosclerosis agents and certain protected intermediates useful in the preparation of said steroidal glycosides.

Abstract: A method of preventing tissue damage resulting from ischemia, comprising administering to a patient in need of such treatment an effective amount of a sorbitol dehydrogenase inhibitor.

Abstract: Compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates of either entity, wherein A is optionally monosaturated C.sub.1 -C.sub.4 alkylene optionaly monounsaturatred with C.sub.1 -C.sub.4 alkyl; B is C.sub.1 -C.sub.3 alkylene optionally substituted with C.sub.1 -C.sub.4 alkyl; R.sup.1 is N-amidino-4-piperidyl or 4-amidinophenyl; R.sup.2 is C.sub.4 -C.sub.12 alkyl; (C.sub.3 -C.sub.8 cycalkyl)C.sub.1 -C.sub.4 alkylene; optionally methylene-bridged C.sub.5 -C.sub.8 cycloalkyl optionally substituted with one to three C.sub.1 -C.sub.4 alkyl groups or with hydroxy; C.sub.5 -C.sub.8 alkenyl; C.sub.5 -C.sub.8 cycloalkenyl optionally subsituted with C.sub.1 -C.sub.4 alkyl; piperidyl N-substituted with C.sub.1 -C.sub.4 alkyl; tetrahydrothiopyranyl or tetrahydropyranyl; and R.sup.3 is H or C.sub.1 -C.sub.4 alkyl optionally substituted with C.sub.1 -C.sub.4 alkoxy or with hydroxy; or R.sup.2 and R.sup.

Abstract: An apparatus for maintaining the sterilization of a reactor vessel output. The apparatus comprises a connect means for connecting to and enclosing the reactor vessel output and a steam trap means for maintaining steam pressure. The steam trap means is in fluid communication with and downstream from both the connect means and an output means for releasing pressure. The output means is in fluid communication with and downstream from the connect means and the output means is upstream from the steam trap means. This apparatus provides a significant improvement to the fermentation industry by facilitating the maintenance of a sanitized sampling output.

Abstract: Certain 5,10-dihydropyrimido?4,5-b!quinolin-4(1 H)-one compounds, and their pharmaceutically-acceptable salts, are useful as inhibitors of tyrosine kinase enzymes and for the treatment of tyrosine kinase dependent diseases (e.g., cancer, atherosclerosis, antiangiogenesis).

Abstract: A process for separating a natural B avermectin from a natural avermectin containing fermentation broth by using an aqueous precipitation. The process comprises extracting natural avermectins from the fermentation broth with a water miscible solvent and adding sufficient water to precipitate the natural B avermetins. Preferably, the water miscible solvent is a C.sub.1 -C.sub.3 alcohol, acetone, or acetonitrile. In addition, an acid, base, salt or surfactant may be added to facilitate the precipitation. This invention provides an isolation technique that substitutes the use of an aqueous precipitation for nonaqueous solvent precipitations. The reduction in use of nonaqueous solvents provides economic, environmental and safety benefits.

Abstract: Darifenacin, and its pharmaceutically acceptable salts, are useful in the treatment of cognitive impairment. The invention also discloses the use of combinations of darifenacin, or a pharmaceutically acceptable salt thereof, with an acetylcholinesterase inhibitor, in the treatment of cognitive impairment.

Abstract: An osmotic device that, following the imbibement of water vapor, provides for the controlled release of a beneficial agent to an aqueous environment. The device comprises a hydrophilic formulation including a beneficial agent, and if needed, an osmagent, surrounded by a wall. The wall is formed at least in part of a semipermeable hydrophobic membrane having an average pore size between about 0.1 .mu.m and 30 .mu.m. The pores are substantially filled with a gas phase. The hydrophobic membrane is permeable to water in the vapor phase and the hydrophobic membrane is impermeable to an aqueous medium at a pressure less than about 100 Pa. The beneficial agent is released, for example, by osmotic pumping or osmotic bursting upon imbibement of sufficient water vapor into the device core.

Abstract: Pharmaceutical combination compositions including certain cholesterol absorption inhibitors and cholesterol synthesis inhibitors. The compositions are useful for the treatment of hypercholesterolemia and atherosclerosis.

Abstract: Crystalline spirostanyl glycosides and processes for making them are disclosed. The crystalline spirostanyl glycosides are useful for treatment of hypercholesterolemia or atherosclerosis.

Abstract: This invention relates to devices useful for the controlled delivery of one or more beneficial agents to an environment of use. More specifically, this invention concerns such devices which are powered by hydrogel. This invention also relates to the controlled delivery of one or more beneficial agents to an aqueous environment of use through the use of such hydrogel powered dispensing devices. Also disclosed are methods for the controlled delivery of one or more beneficial agents to an aqueous environment of use which comprises administering to or otherwise placing the devices of this invention in the environment of use.

Abstract: Compounds of the formula ##STR1## wherein: Q is naphthyl, heterocyclic or heterobicyclic; R.sup.1 and R.sup.2, when taken separately, are hydrogen, hydroxy, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenyl, heterocyclic or heterobicyclic; R.sup.1 and R.sup.2, when taken together, form a carbocyclic, carbobicyclic, heterocyclic or heterobicyclic group; R.sup.3 is --(CH.sub.2).sub.n COR.sup.4, tetrazolyl, alkyltetrazolyl, triazolyl, alkyltriazolyl, --(CH.sub.2).sub.n CH.sub.2 OH, --SO.sub.2 R.sup.4, --SO.sub.2 NR.sup.5 R.sup.6 or --NHSO.sub.2 R.sup.7 ; R.sup.4 is hydrogen, hydroxy, --NR.sup.5 R.sup.6, --NHSO.sub.2 R.sup.7, alkoxy, alkylthio, --NR.sup.5 R.sup.6, --NHSO.sub.2 R.sup.7 or --OY; n is 0 to 5; Y is a pharmaceutically acceptable cation or a group hydrolyzable under physiological conditions; R.sup.5 and R.sup.6, when taken separately, are hydrogen, alkyl, --CONRR, --COOR or --CO(C.sub.6 H.sub.5); R.sup.5 and R.sup.6, when taken together, form an azacyclic ring; R.sup.

Abstract: This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents and antiatheroscierosis agents.

Abstract: A crystalline monohydrate of (3.beta.,5.alpha.,25R)-3-?(.beta.-D-cellobiosyl)oxy!spirostan-11-one that is useful as a hypocholesterolemic or antiatherosclerosis agent.

Abstract: This invention relates to certain 4-aminoquinazolines and the pharmaceutically acceptable salts and stereoisomers thereof, the formula whereof are described herein. The compounds are useful for the treatment of hyperproliferative diseases, particularly as anti-cancer agents.